Ezekowitz Alan 4
Research Summary
AI-generated summary
Fulcrum Therapeutics (FULC) Director Alan Ezekowitz Sells 18,000 Shares
What Happened
Alan Ezekowitz, a director of Fulcrum Therapeutics (FULC), sold 18,000 shares on June 26, 2026. The weighted average sale price was $3.65 per share, for total proceeds of approximately $65,614. This was a disposition (sale), not a purchase.
Key Details
- Transaction date: 2026-06-26; Form 4 filed: 2026-06-30 (filed within the required 2 business days).
- Shares sold: 18,000; weighted average price reported: $3.65; total proceeds: $65,614.
- Price range: shares were sold in multiple trades at prices from $3.555 to $3.82 (inclusive). The filer will provide a per-price breakdown on request.
- Reported as sale (Code S) via open market or private sale.
- The sales were effected under a Rule 10b5-1 trading plan adopted by Ezekowitz on March 27, 2026.
- Shares owned after the transaction: not disclosed in this Form 4 excerpt.
Context
A 10b5-1 plan allows insiders to execute pre-arranged trades and is commonly used to avoid questions about timing; transactions under such plans are generally considered routine and do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases by insiders often carry more weight as a bullish signal; recorded sales like this primarily show liquidity or routine portfolio management rather than an explicit vote on company prospects.